Anti il 12p40 clone c17

Manufactured by BioXCell

Anti-IL-12p40 (clone C17.8) is a monoclonal antibody that binds to the p40 subunit of interleukin-12 (IL-12). It is used as a research tool for the detection and quantification of IL-12p40 in various biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd8β clone lyt 3, by BioXCell (3 mentions) Anti ifn γ clone r4 6a2, by BioXCell (3 mentions) Anti cd4 clone gk1, by BioXCell (3 mentions) Anti pd l1 ab clone 10 f 9g2, by BioXCell (2 mentions) Rat igg2b clone ltf 2, by BioXCell (2 mentions) Anti nk1.1 clone pk136, by BioXCell (1 mentions) Igg2a isotype control clone 2a3, by BioXCell (1 mentions)

5 protocols using anti il 12p40 clone c17

Radiation-Induced Immune Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

For PD-L1 blockade, anti-PD-L1 Ab (clone 10 F.9G2, BioXcell), or rat IgG2b (clone LTF-2, BioXcell) were given intraperitoneally (i.p.) every third day from the day RT performed at a dose of 200 μg/mouse. For in vivo depletion of lymphocytes, 200 μg of anti-CD4 (clone GK1.5, BioXcell), anti-CD8β (clone Lyt 3.2, BioXcell), anti-NK1.1 (clone PK136, BioXcell) Abs, or rat IgG2b (clone LTF-2, BioXcell) Ab were injected i.p. every third day for three times from the day when RT was given. For in vivo depletion of IL-12 and IFN-γ, 1 mg of anti-IL-12p40 (clone C17.8, BioXcell) and anti-IFN-γ (clone R4⁻6A2, BioXcell) Abs were administrated by i.p. injection at the day when RT was performed, with follow-up doses of 500 μg for five consecutive days.

Oba T., Long M.D., Keler T., Marsh H.C., Minderman H., Abrams S.I., Liu S, & Ito F. (2020). Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nature Communications, 11, 5415.

+ Open protocol

+ Expand

Modulating Tumor Immunity with Anti-PD-L1 and T-Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols

For anti PD-L1 therapy, anti-PD-L1 Ab (clone 10F.9G2, BioXcell) was given intraperitoneally (i.p.) every third day from the day RT performed at a dose of 200 μg/mouse. Rat IgG2b Ab (clone LTF-2, BioXcell) was used as a control. To deplete CD8⁺ and CD4⁺ T cells, 200 μg of anti-CD8β (clone Lyt 3.2, BioXcell) and anti-CD4 (clone GK1.5, BioXcell) Abs were administrated i.p. every third day for three times from the day when RT was given, respectively. To neutralize IL-12 and IFN-γ, 1 mg of anti-IL-12p40 (clone C17.8, BioXcell) and anti-IFN-γ (clone R4-6A2, BioXcell) Abs were injected by i.p. at the day when RT was performed, with follow-up doses of 500 μg for 5 consecutive days.

Patel A., Oba T., Kajihara R., Yokoi T., Abrams S.I, & Ito F. (2021). Multimodal intralesional therapy for reshaping the myeloid compartment of tumors resistant to anti-PD-L1 therapy via IRF8. Journal of immunology (Baltimore, Md. : 1950), 207(5), 1298-1309.

+ Open protocol

+ Expand

Immune Modulation Protocols for Cancer Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

For PD-1 blockade, aPD-1 Ab (Bio X Cell), or rat IgG2b (clone LTF-2, Bio X Cell) were given intraperitoneally (i.p.) every third day from the first day ISV was performed at a dose of 200 µg/mouse. For in vivo depletion of lymphocytes, 200 µg of anti-CD4 (clone GK1.5, Bio X Cell), anti-CD8β (clone Lyt 3.2, Bio X Cell), or rat IgG2b (clone LTF-2, Bio X Cell) were injected i.p. every third day three times from the first treatment day. For in vivo depletion of IL-12 and IFN-γ, 1 mg of anti-IL-12p40 (clone C17.8, Bio X Cell) and anti-IFN-γ (clone R4⁻6A2, Bio X Cell) Abs were administrated by i.p. injection at the first treatment day, with follow-up doses of 500 µg for five consecutive days.

Mao C., Beiss V., Ho G.W., Fields J., Steinmetz N.F, & Fiering S. (2022). In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. Journal for Immunotherapy of Cancer, 10(12), e005834.

+ Open protocol

+ Expand

Inducing Acute Viral Infections and Immunity in Mice

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

For acute infections and to establish immunity, mice were infected i.p. with 1 × 10⁵ PFU of Armstrong LCMVclE350 (7 (link), 8 (link)). For secondary viral infections at times ≥2 months after primary LCMV infection (≥2 mpi), mice were i.v. challenged with 4 × 10⁶ PFU of LCMVcl13 (18 (link)) or infected i.p. with 1 × 10⁴ to 1.5 × 10⁴ PFU of salivary gland-derived MCMV as previously described (34 (link)). For neutralization of IL-12, LCMV-immune mice were given 0.75 mg of either anti-IL-12p40 (clone C17.8) or an IgG2a isotype control (clone 2A3), both from BioXCell, at 12 h prior to infection with MCMV.

Suarez-Ramirez J.E., Tarrio M.L., Kim K., Demers D.A, & Biron C.A. (2014). CD8 T Cells in Innate Immune Responses: Using STAT4-Dependent but Antigen-Independent Pathways to Gamma Interferon during Viral Infection. mBio, 5(5), e01978-14.

+ Open protocol

+ Expand

Reversal of Tumor-Induced T Cell Anergy

Check if the same lab product or an alternative is used in the 5 most similar protocols

To elicit tumor-induced anergic T cells, congenic OT-I^Thy1.1 or pmel-1 cells (sorted CD8⁺) were adoptively transferred into B6 hosts, then mice were implanted with bilateral tumors (B16-OVA or B16F10, respectively). After 14 days, the anergic T cells were sorted from TDLNs (Thy1.1⁺CD8⁺). To test for rescue by Ly6c⁺CD103⁺ monocytic cells, B16-OVA tumors were implanted in different mice, then treated with CTX+VO-OHpic. Cells were enriched by sorting for Ly6c⁺CD11c⁺ cells, as above; then 5×10³ Ly6c⁺CD11c⁺ cells co-cultured with 5×10⁴ anergic OT-I cells sorted from TDLNs. (For rescue of anergic T cells, the feeder layer and Treg cells used in the maturation cultures were not necessary and were omitted.) Co-cultures were set up in triplicate and proliferation measured after 3 days by ³H-thymidine incorporation. Some wells received recombinant IL-12 (R&D systems, #419-ML/CF, 40 ng/ml) or IL-12 neutralizing antibody (anti-IL-12p40, clone C17.8, BioXcell, 1 ug/ml).

Sharma M.D., Rodriguez P.C., Koehn B.H., Baban B., Cui Y., Guo G., Shimoda M., Pacholczyk R., Shi H., Lee E.J., Xu H., Johnson T.S., He Y., Mergoub T., Venable C., Bronte V., Wolchok J.D., Blazar B.R, & Munn D.H. (2018). Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c+CD103+ monocytic antigen-presenting cells in tumors. Immunity, 48(1), 91-106.e6.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!